# Clifutinib

Source: https://onco.cc/drugs/clifutinib/  
OnCo record `clifutinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.

## Summary

Clifutinib (HEC73543) is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05586074 (HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML), in acute myeloid leukaemia. The largest, NCT05586074, plans to enrol 324 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: HEC73543
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Clifutinib: https://clinicaltrials.gov/search?intr=HEC73543

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- trials: [A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML](https://onco.cc/trials/nct05133882/), [HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML](https://onco.cc/trials/nct05586074/)
- companies: [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/)

---
JSON: https://onco.cc/api/v1/entities/clifutinib.json